2 terminated, 1 completed. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 2, Completed 1 |
Follow IPI-145 (duvelisib): new trials by email Literature Review of IPI-145 (duvelisib) trials Research Report on IPI-145 (duvelisib)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Duvelisib With Obinutuzumab in Patients With CLL/SLL Previously Treated With a BTKi (SYNCHRONY) IPI-145 (duvelisib), Obinutuzumab - Lymphocytic Leukemia, Chronic, Lymphoma, Small Lymphocytic | Phase 1 | Terminated | SecuraBio | 3 | 2015-02-01 | 2023-02-27 |
| Bioequivalence of Duvelisib and Food Effect on Pharmacokinetics of IPI-145 IPI-145 (duvelisib), IPI-145 - Healthy | Phase 1 | Completed | SecuraBio | 103 | 2014-11-01 | 2021-03-17 |
| A Phase 1 Study of Duvelisib in Patients With Advanced Hematologic Malignancies IPI-145 (duvelisib) - Hematologic Malignancies | Phase 1 | Terminated | SecuraBio | 210 | 2011-10-01 | 2021-03-17 |
Hematologic Neoplasms (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1)
SecuraBio (3)
United States (3) · Canada (1)